Vertex to acquire Crinetics in $10B foray into endocrine disease drugs

AI Summary

Vertex Pharmaceuticals is acquiring Crinetics in a $10 billion deal to expand its portfolio in endocrine disease drugs. The deal highlights expectations for the two drugs involved to potentially generate over $5 billion annually, despite concerns from analysts and investors about the high acquisition cost.

Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it paid stirred debate among analysts and investors.